The FDA has approved the neuromodulator injection Daxxify for the temporary improvement of moderate to severe glabellar lines, Revance Therapeutics Inc. announced in a press release.
Daxxify (DaxibotulinumtoxinA-lanm) is the first neuromodulator stabilized with Peptide Exchange Technology and is free of human serum albumin and animal-based components.
The approval was based on data from the SAURA phase 3 clinical trial program in which 74% of patients achieved a 2-grade or more improvement in glabellar lines at week 4 as assessed by both investigator and patients, and 88% achieved a 2-grade or